Clinical Report: Investigation of Blood Transcriptome Alterations Following Mepolizumab Therapy in Severe Eosinophilic Asthma Patients

Overview

This study evaluates the impact of mepolizumab therapy on the blood transcriptome in patients with severe eosinophilic asthma. Key findings indicate limited global transcriptomic changes and some differential expression of genes associated with treatment response.

Background

Severe eosinophilic asthma (SEA) is a significant subset of asthma characterized by eosinophilic inflammation and high healthcare utilization. Understanding the transcriptomic alterations following anti-IL-5 therapy, such as mepolizumab, is crucial for improving treatment strategies and patient outcomes. This study aims to explore these changes to enhance the understanding of SEA pathophysiology.

Data Highlights

No definitive mechanistic or predictive response signatures were identified due to study limitations.

Key Findings

• 149 genes showed significant differential expression at week 12 compared to baseline.
• 74 genes were downregulated at weeks 4, 8, and 12 compared to baseline.
• 28 genes changed over time and were associated with response to therapy.
• 56 protein-coding genes distinguished responders from nonresponders.
• Nonresponders exhibited high enrichment of genes involved in signaling pathways at week 12.

Clinical Implications

The findings suggest that while mepolizumab therapy leads to some changes in gene expression, the overall transcriptomic response is limited. Clinicians should consider these findings when evaluating treatment responses and may need to explore additional biomarkers for predicting therapy outcomes.

Conclusion

This exploratory study highlights the complexity of transcriptomic responses to mepolizumab in SEA patients, indicating the need for further research to elucidate the underlying mechanisms and improve predictive capabilities.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Is blood eosinophilia a treatable trait in chronic obstructive airway diseases?
2. Drug Safety, 2020 -- Evaluating the Safety of Benralizumab in Eosinophil-Depleting Treatment for Severe Eosinophilic Asthma
3. Frontiers in Medicine, 2026 -- Resident eosinophils in patients with chronic obstructive pulmonary disease: a pilot study
4. 2026 GINA Strategy Report - Global Initiative for Asthma - GINA
5. Efficacy and safety of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis - Li - Journal of Thoracic Disease
6. The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma - PubMed
7. conexiant — Personalizing Steroid Duration in Asthma
8. 2026 GINA Strategy Report - Global Initiative for Asthma - GINA
9. Efficacy and safety of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis - Li - Journal of Thoracic Disease
10. The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma - PubMed